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Novel genetic mutations in genes AGBL5 and TULP1 for presumed unilateral
retinitis pigmentosa managed with low vision rehabilitation: A case report and
review
Abstract
Background: Retinitis pigmentosa is a group of hereditary retinal diseases characterized by the
degeneration of rod and cone photoreceptors. It commonly results in night blindness followed by tunnel
vision and central vision reduction. The classic triad of clinical signs includes pigmented bone spicules,
waxy disc pallor, and arterial attenuation. Unilateral retinitis pigmentosa is rare and can be supported with
ancillary testing including genetic and laboratory studies to rule out differential diagnoses.
Case Report: A 68-year-old Hispanic female was referred to the low vision rehabilitation clinic due to
progressive vision loss in the left eye (OS) that began 15 years ago. The vision was normal in the right eye
(OD). Additionally, she suffered from hearing loss in the right ear since age 3. Examination revealed
abnormal visual acuity, visual field, fundus appearance, optical coherence tomography, and
electrodiagnostic test results in the OS only. Laboratory studies ruled out various infectious, autoimmune,
traumatic, and toxic drug etiologies. Genetic testing revealed novel mutations in genes associated with
retinitis pigmentosa.
Conclusion: The genetic testing results along with the clinical examination and electrodiagnostic
evaluation supports the diagnosis of unilateral retinitis pigmentosa.
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INTRODUCTION
Retinitis pigmentosa (RP) is a genetically inherited group of disorders affecting 1
in 5,000 people worldwide and 1 in 4,000 in the United States.1 It is commonly
bilateral with a variety of presentations and progressions. The initial symptom is
night blindness followed by reduced peripheral visual field. During the later stages
of the disease, color and central vision become affected.2 Characteristic fundus
features include pigmented bone spicules, waxy disc pallor, and arterial attenuation.
Other ocular findings include cystoid macular edema and posterior subcapsular
cataract. The genetic inheritance pattern of RP varies, and may be autosomal
dominant, autosomal recessive, X-linked recessive, or sporadic.1
Although there is no cure for retinitis pigmentosa, there are options for supportive
care. One example is nutriceutical vitamin supplementation. Research has shown
that taking a high dose of vitamin A palmitate (15,000 IU daily), omega-3 rich
foods, and a lutein supplement may slow the progression of RP.2,3 Additional
prophylactic measures include protective sunglasses and avoiding smoking, since
exposure to ultraviolet light and smoking increases oxidative damage and
accelerates retinal degeneration.3 If sequelae occur, such as cystoid macular edema,
off-label carbonic anhydrase inhibitors may be considered and have been reported
to have a response rate of 40 to 50%.4,5
Gene and stem cell therapies are two exciting and rapidly evolving areas of
research. For those patients with RPE65 mutations, a novel gene therapy,
Luxturna®, was approved in December of 2017 by the Food and Drug
Administration (FDA). This was the first FDA approved gene therapy for an
inherited disease in the United States.2,6,7 Gene and stem cell therapies may slow
retinal degeneration in RP and may also improve visual function.8 Several clinical
trials targeting other genetic mutations for RP are currently underway.8,9
RP is a heterogenous group of retinal dystrophies with several sequelae resulting
from different subtypes described. Reclassification of some of these variants is
likely as we uncover the molecular pathogenesis and define different presentations
of the disease. Some clinical differentials of RP include:
- Minor asymmetrically bilateral RP: The common form of RP is bilateral, but
the disease progresses faster in one eye compared to the fellow eye. This results
in minor asymmetry in RP presentation.10
- Unilateral RP (URP): The first case of URP was described in 1948 by Dreisler.10
Since then, nearly 100 cases of URP have been reported based on the following
criteria established by Francois and Verriest: (i) unilateral ocular RP
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presentation, (ii) normal fundus appearance and electroretinogram (ERG)
findings in the fellow eye, (iii) exclusion of infectious etiology, and (iv)
sufficiently long period of observation (more than 5 years).11,12 These criteria
have been supported by later studies, however, there is still controversy
concerning the nature of this clinical presentation.13-16
- Pseudo-RP: There are several etiologies that can mimic RP including infection
(i.e., syphilis, toxoplasmosis, rubella, chicken pox, measles, cytomegalovirus),
inflammation (i.e., uveitis, retinal vasculitis), autoimmunity (i.e., cancerassociated retinopathy), trauma (i.e., blunt trauma, retinal detachment), or drug
toxicity (i.e. chloroquine/hydroxychloroquine, phenothiazines,
thioridazine).17,18
From a low vision standpoint, there are options available throughout the course
of vision loss when the condition presents bilaterally. For patients with early vision
loss, non-optical aids can be helpful. Some of these include a flashlight for night
mobility and a mobility cane. Optically, reverse telescopes to enhance the
peripheral field can be helpful in addition to magnification devices for central
vision loss. In the past, for patients with end-stage RP (i.e., light perception or
worse), an Argus II Retinal Prosthesis implant was considered.2 This implant sent
a signal downstream of the affected retina in the visual pathway, restoring some
movement detection and resolution of shapes. (This device is limitedly available.)
Regardless of the stage of vision loss and treatment, patients with RP will benefit
from management through a coordinated team effort.
In this manuscript we describe the clinical and molecular findings in a patient with
a unilateral and progressive form of retinal degeneration. We will also discuss a
potential diagnosis of unilateral RP based on clinical history and genetic findings.
Although our patient did not exhibit bilateral loss, a brief explanation of how low
vision rehabilitation can help in cases of bilateral retinitis pigmentosa will also be
presented.
CASE REPORT
A 68-year-old Hispanic female was referred to the low vision rehabilitation clinic
due to progressive vision loss of her left eye (OS) that began 15 years prior. She
had no visual complaints regarding her right eye (OD). She reported that her OS
had fundus findings compatible with RP in her early 40’s.
Her medical history included hypercholesterolemia, type 2 diabetes mellitus
diagnosed 6 months ago (uncertain if controlled at initial presentation), and hearing
loss in the right ear diagnosed when she was 3 years old (presumably associated
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with maternal rubella). She denied any history of trauma, retinal detachment,
infectious or inflammatory disease. She had no known allergies. Medications
included ibuprofen 600 mg, aspirin 81 mg, atorvastatin 20 mg, lisinopril 5 mg,
omeprazole 20 mg, and captopril 25 mg. She was not on diabetic medications. She
was a former occasional smoker but denied alcohol consumption or recreational
drug use. Her family history included a paternal uncle with vision loss of unknown
etiology.
At presentation, her best-corrected visual acuities were 20/20 OD and 20/40 OS.
Contrast sensitivity testing showed slight reduction in OD (log 1.50) and severe
reduction OS (log 0.75). Pupil testing revealed a 3 to 4+ relative afferent pupillary
defect OS. A 120-point screening automated Humphrey visual field demonstrated
115/120 points seen OD and 0/120 points seen OS with a size III white
stimulus(Figure A.1a).

Figure A.1a. 120 point visual field showing an essentially full field OD, and near-total visual field
loss OS. The HVF 30-2 shows some central vision sparring OS.

Fundus evaluation revealed senescent macular changes and atypical scattered
granular white dots throughout the midperiphery in both eyes (Figures A.2, OD and
A.3 for OS). In the OD, extensive drusenoid deposits were present in the macula
and posterior pole consistent with intermediate stage nonexudative age-related
macular degeneration (Figure A.2).
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Figure A.2. Fundus photo OD showing drusen throughout the macula and posterior pole.

Figure A.3. Two fundus photos of OS showing patchy areas of RPE atrophy, bone-spicule shaped
RPE hyperplasia, arteriolar attenuation, choroidal vessel sclerosis, optic atrophy, and mild macular
drusen.

The optic nerve head appeared normal with a 0.3 cup-to-disc ratio and the retinal
vasculature was unremarkable aside from a mildly enlarged arteriolar light reflex.
Minor pigmentary changes were present OD, and only a single locus of retinal
pigment epithelium (RPE) hyperplasia was present along a retinal vessel in the
nasal midperiphery. Fundus autofluorescence (FAF) imaging OD revealed pinpoint
scattered speckled or granular mixed hypofluorescent and hyperfluorescent
changes throughout the posterior pole (Figure A.4).
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Figure A.4. FAF imaging showing scattered pinpoint speckles of mixed hypofluorescent and
hyperfluorescent changes and a ring of hypofluorescence surrounding the optic nerve head OD. FAF
imaging OS shows patchy and geographic-shaped areas of hypoflourescence that are confluent
surrounding the optic nerve, as well as mild relative hyperflourescence in the remaining macular
region.

Few large-sized drusen in the macular region corresponded to rings of
hyperfluorescence with central hypofluorescence. Additionally, a ring of
hypofluorescence surrounding the optic nerve head was present consistent with
nonpathologic peripapillary atrophy. Structural optical coherence tomography
(OCT) OD confirmed the presence of large-sized soft drusenoid deposits within the
macular region. OCT angiography OD demonstrated normal appearing inner retinal
vasculature, however, mild focal perfusion deficits were present within the
choriocapillaris underlying areas of drusen (Figure A.5). No signs of exudative agerelated macular degeneration (such as fluid or choroidal neovascularization) were
present with OCT and OCT angiography imaging.

Figure A.5. OCT angiography demonstrating decreased choriocapillaris and retinal perfusion OS.
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Ophthalmoscopy OS revealed mild drusenoid deposits within the macula and
scattered throughout the posterior pole, however, drusenoid changes were far less
extensive OS compared to OD (Figure A.3). Patchy areas of RPE atrophy and
classic appearing bone-spicule shaped RPE hyperplasia were present throughout
the posterior pole and periphery OS. The retinal vasculature demonstrated severe
diffuse arteriolar attenuation and moderate attenuation of the retinal veins. The
large chorodial vessels had a whitened appearance consistent with vascular
sclerosis. Severe and diffuse pallor of the neuroretinal rim tissue without cupping
was present OS. The cup-to-disc ratio was measured as 0.4. FAF imaging OS
revealed patchy and mostly geographic-shaped areas of hypoflourescence that were
confluent surrounding the optic nerve (Figure A.4). Additionally, mild relative
hyperflourescence appeared to be present in the remaining macular and foveal
regions. OCT angiography OS revealed decreased perfusion in both the retinal and
choriocapillaris circulatory systems (Figure A.5). Near total choriocapillaris
dropout was present underlying circular geographic areas of RPE loss within the
superior macula (Figure A.5). Structural OCT imaging OS demonstrated outer
retinal and RPE atrophy with loss of the ellipsoid zone, or photoreceptor integrity
line, throughout the macula that spared the foveal region. Few hyperreflective hard
drusenoid-type subretinal deposits were present (Figure A.6). Optic nerve head and
nerve fiber layer (NFL) OCT imaging showed probable inferior and superior NFL
loss OS as well as a relative decrease in NFL thickness OS as compared to OD
(Figure A.7).

Figure A.6. Structural macular OCT imaging OS demonstrating outer retinal and RPE atrophy
with loss of the ellipsoid zone throughout the macula that spares the center of the fovea.
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Figure A.7. Optic nerve head and NFL OCT showing probable inferior and superior NFL loss
OS as well as a relative decrease in average NFL thickness OS as compared to OD.

A series of electrodiagnostic tests were performed to evaluate retinal function. A
Diopsys® full-field ERG was obtained utilizing a red flash on a blue background.
This waveform appeared normal OD, however, the response OS was nearly
extinguished with reduced A-wave, B-wave and photoptic negative response
amplitudes (Figure A.8).
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Figure A. 8. Diopsys® full-field ERG obtained utilizing a red flash on a blue background showing
normal response OD and near extinguished response OS.

Similarly, Diagnosys® dark-adapted full-field flash ERGs revealed normal A and
B-waves OD, and a severely reduced response OS (Figure A.9). Focusing on more
localized areas of reduction, the multifocal ERG demonstrated mild reduction in
the OD and severe reduction in the OS responses. A contrast sensitivity ERG
(which detects functional performance of retinal ganglion cells) showed normal
response OD and reduced response OS.
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Figure A.9. Diagnosys® light-adapted flicker ERG (left) and dark-adapted full-field flash ERG
(right). Dark-adapted full-field flash ERG shows normal A and B-waves OD, and near extinguished
response OS.

Additional information including bloodwork and carotid ultrasound imaging was
ordered to rule out any attributable infectious, inflammatory, autoimmune, or toxic
retinal disease process. The following test results were within normal limits
(summarized on Table B.1): complete blood count (CBC), comprehensive
metabolic panel, erythrocyte sedimentation rate (ESR), rapid plasma reagin (RPR),
fluorescent treponemal antibody absorption (FTA-ABS), Lyme antibody,
toxoplasma antibody, and lupus panel. However, C-reactive protein (CRP) was
elevated at 20.0 mg/L, outside the normal range of < 8 mg/L, and glucose and blood
urea nitrogen (BUN) to creatinine ratio were also flagged as high. Blood glucose
was 116 mg/dL, outside the normal range of 65-99 mg/dL, consistent with her
history of type 2 diabetes. Because she had hypercholesteremia, we attributed the
elevated CRP to be an inflammatory marker for associated cardiovascular disease.
Her most current carotid ultrasound revealed patent carotid and vertebral arteries
bilaterally.
Components

Results

Components

Results

Carotid/vertebral
arteries
RPR
Lyme Ab
Toxoplasma Ab
CBC
Comp metabolic panel

WNL

ESR

WNL

WNL
WNL
WNL
WNL
WNL

FTA-ABS
Lupus panel
CRP
Glucose
BUN/creatine

WNL
WNL
High: 20.0 mg/L,
High: 116 mg/dL
High

Table B.1. Laboratory studies showing within normal levels (WNL) values for all components
except C-Reactive Protein (CRP), glucose, and BUN/creatine ratio.
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To further assist in the diagnosis, the patient underwent genetic testing via a
research program sponsored by the Foundation Fighting Blindness. Sequence
analysis using the Blueprint Genetics (BpG) Retinal Dystrophy Panel Plus
identified heterozygous missense mutations in AGBL5 [c.14466G>A, p.
(Arg489His)] and TULP1 [c.38C>A, p. (Ala13Asp)] genes. These genetic changes
were classified as Variants of Uncertain Significance (VUS) because they are
inherited with an autosomal recessive pattern and thus, in heterozygosity, were not
consistent with a diagnosis of bilateral RP. The patient was educated on RP and
counseled on the genetic findings.
While URP did not necessitate low vision rehabilitation, the co-morbidity of
AMD with advanced peripheral field loss OS did. So, management with low vision
rehabilitation was implemented. Recommendations included a yellow filter to
subjectively enhance contrast sensitivity binocularly as both eyes had minimal
reduction in contrast sensitivity, and good, direct illumination on her tasks to
enhance contrast. To address the near total field loss on her left side, we provided
training on scanning her environment to the left and wearing single vision distance
spectacles. It was recommended that she perform a behind the wheel driving
evaluation with the Department of Motor Vehicles as well. This was suggested as
a protective measure for the patient as the state driving law has a recommended,
thought not required, minimum horizontal angle of vision.
DISCUSSION
URP is a rare disease that usually presents more commonly in adults.14,15 It has
later onset than bilateral RP and a definitive diagnosis requires thorough
investigation including confirmation of normal ERG tests and exclusion of
asymmetrical RP as well as other infectious, inflammatory, traumatic, toxic, and
vascular retinal conditions.14,19 For this patient the clinical presentation,
progression of vision loss, and the results of anciliary tests were consistent with
URP and fit most of the criteria for URP diagnosis proposed by Francois and
Verriest.11,15 These criteria include: (i) unilateral ocular RP presentation, (ii) normal
fundus appearance and electroretinogram (ERG) findings in the fellow eye, (iii)
exclusion of infectious etiology, and (iv) sufficiently long period of observation
(more than 5 years). In our patient, fundus findings consistent with RP were present
in the OS, with only a single locus of RPE hyperplasia present along a retinal vessel
in the nasal midperiphery in the OD. ERG testing was normal OD and laboratory
testing ruled out an attributable infectious disease. Additionally, our patient was
diagnosed with RP in the OS approximately 25 years prior to her examinations at
our clinic.
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There are characteristic fundus features and anciliary test findings that aid with
the diagnosis of RP. In our patient, fundoscopy revealed the pigmentary bone
spicules, arteriolar attenuation, and disc pallor in the OS which directed us to a
diagnosis of RP. The bilateral drusen was worse OD, and is indicative of coexisting
nonexudative age-related macular degeneration. Otherwise, the fundus appearance
OD lacked the distinctive signs of RP. ERG provided a quantitative objective
measurement of retinal function,2,20 with photopic and scotopic ERG results
severely reduced in the affected eye and normal in the fellow eye, as expected in
an individual with URP.
Fundus autofluorescence imaging reflects retinal metabolism as well as the
amount and distribution of lipofuscin.21 Therefore, hypofluorescence is suggestive
of disruption or loss of the photoreceptors and/or RPE, while hyperfluorescence is
suggestive of retinal stress and impending degeneration. It often reveals even subtle
RPE damage that may be difficult to detect with funduscopic examination alone.
Fundus autofluorescence imaging in our patient helped highlight widespread and
large areas of RPE atrophy that spared the foveal region OS and supported our
presumed diagnosis of RP. Her OS also exhibited mild hyperfluorescence within
the remaining macular/foveal region which is a well-described FAF feature in eyes
with RP.22 In contrast, FAF imaging OD lacked characteristic features of RP such
as midperipheral hypofluorescence and macular hyperfluorescence. The diffuse
stippled hyper/hypofluorescence pattern present in the posterior pole OD is likely
atrributable to nonexudative age-related macular degeneration.
Optical coherence tomography demonstrated outer retinal and RPE atrophy with
relative foveal sparing OS only, which is consistent with URP. The intact foveal
ellipsoid zone OS is consistent with the relatively good visual acuity. Asymmetric
decreased choriocapillaris perfusion, more severe in the OS, was visualized by OCT
angiography imaging and is likely attributable to age-related macular degeneration
in her OD alone and the combination of advanced RP and age-related macular
degeneration in her OS. Additionally, the retinal perfusion was also drastically
reduced OS (compared to OD) which is consistent with URP, since research
suggests that both reduced retinal and choriocapillaris perfusion are manifestations
of RP.23
The patient experienced moderate hearing impairment in one ear with an intact
vestibular system diagnosed early in life. Her symptoms did not correlate with
Usher syndrome or other types of syndromic RP. (Usher syndrome is classified
into three subtypes including USH type I, type II, and type III.24,25 Type I is the
most severe, presenting with profound to total deafness, vestibular dysfunction, and
progressive RP at birth. Type II is as common, but not as severe as type I, presenting
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with variable degree of hearing impairment, intact vestibular system, and RP onset
at puberty. Type III presents with moderate deafness, inconsistent vestibular
dysfunction, and RP symptoms.) The patient’s mother was infected with rubella
during pregnancy, and there is ample evidence indicating that maternal rubella can
lead to hearing loss and retinopathy either bilaterally or unilaterally.26 However, the
patient had congenital hearing loss of the right ear while retinopathy was diagnosed
only during her fifth decade of life in the contralateral eye. Given this, maternal
rubella could explain her congenital hearing loss but it is unlikely related to her
retinal disease.
Pseudo-RP due to infection, autoimmunity, trauma, or drug toxicity were ruled
out with laboratory testing. The patient showed augmented CRP levels, which may
be related to her hypercholesterolemia or uncontrolled diabetic condition (glucose
level of 116 mg/dL; normal range of 65-99 mg/dL). However, an inflammatory
pseudo-RP could not be completely ruled out in this patient and would require
further investigation.
The association between AGBL5 and retinitis pigmentosa 75 was proposed in
2015 and new genetic variants have been discovered since then.27,28 AGBL5
encodes ATP/GTP binding protein like 5 involved in the process of
deglutamylation.29 TULP1 gene is involved in photoreceptor function and the
lifespan of photoreceptor cells.30 Bilateral RP can be caused by homozygous or
compound heterozygous mutations in the autosomal genes AGBL5 and
TULP1.27,29,31 In this case, genetic testing found missense mutations in only one of
the two alleles of these RP-associated genes (heterozygous expression). Whether
or not these changes were causing RP in this case remains elusive. Three
possibilities could explain the pathogenic expression of these gene variants: (I) low
level mosaicism, defined by the presence of at least two cell populations with
different genotypes in her retina, (II) the second mutation could have occurred in
her retina as a somatic event, or (III) the wild type allele could have been silenced
via epigenetic changes. The patient was negative to known X-linked RP pathogenic
variants, which suggested a somatic mutation, mosaicism, or gene silencing as
possible etiologies. This was in agreement with previous reports of unilateral
RP.16,19,32 In order to better assess the distribution and potential role of her genetic
variants in RP, we recommended extending genetic testing to any family member
affected by retinal disease.
A recent study involving over two thousand patients with inherited retinal
dystrophy found that a molecular diagnosis can be achieved via genetic testing in
approximately 70% of patients.33 This leaves up to 30% of all retinal dystrophy
cases without a definitive molecular diagnosis. Thus, although genetic testing is
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informative, further research is needed to obtain the scientific and clinical
knowledge to determine the role of novel mutations, like the ones identified in our
patient. In this regard, the possibility of a novel AGBL5 and TULP1digenic form of
RP cannot be ruled out completely. However, the unilateral presentation in our
patient suggested a retina-specific event (e.g., somatic or epigenetic change) as a
likely second hit. Again, to the best of our knowledge, this is the first report of a
patient with probable URP expressing these two genetic variants in
heterozygosity. Genetic tests for Inherited Retinal Diseases (IRD), like the one
used for our patient, use blood or saliva samples to find genetic changes present in
germline cells. Somatic mutations, low level mosaicism, or epigenetic changes fail
to be detected on these tests. Of note, these have been proposed as mechanisms
driving URP. To find the underlying molecular mechanism that would provide a
definitive diagnosis for the patient, a biopsy of the retinal tissues would be needed.
Based on the clinical findings, her case history, and our quantitative data
combined with her genetic finding of recessive variants expressed in
heterozygosity, we propose either low level mosaicism or a somatic event involving
her OS as a plausible explanation. Her genetic and clinical information has been
included in the My Retina Tracker database and is now available to clinicians and
researchers. Building a community of clinical scientists will enable us to better
correlate genotypes and clinical manifestations in inherited retinal disease and to
improve patient care.
Other clinical tests performed were useful for understanding and addressing the
functional needs of our patient. It is our goal as low vision rehabilitation clinicians
to enable our patients to function in their environment, maintain independence, and
optimize the quality of their lives. Generally, most patients with only one severely
impacted eye do not require low vision services. However, our patient, despite
having a functionally normal OD, had both contrast loss OU and peripheral field
loss OS that affected her bilateral visual function and for which management of
these complaints was within the scope of low vision services. She also had the
coexistence of early age-related macular degeneration in the macula of the OD
more than the OS. Therefore, we felt it was also relevant to educate her on available
resources should there be an eventual progression of macular degeneration.
Contrast sensitivity testing is an alternate method of quantifying the visual
function of an individual. Often contrast sensitivity testing can detect a reduction
in visual function earlier than visual acuity loss and can explain visual complaints
that are disproportionate to acuity loss alone. In this case, our patient was
experiencing severe contrast sensitivity reduction OS and mild to moderate contrast
sensitivity loss OD. We feel this was due to the comorbidity of her macular
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degeneration with RP. Enhancement of contrast sensitivity with yellow filters is a
known treatment option and, in this case, provided our patient with some subjective
improvement in her vision.34 In addition, the contrast enhancement feature of
electronic video magnifiers and digital media, good lighting, and glare filters can
be helpful for both URP and age-related macular degeneration.35-37
The 120 point screening visual field and 30-2 threshold visual fields were used to
assess the patient’s overall functional visual field, both in extent and sensitivity. A
reverse telescope is ordinarily useful to enhance bilateral constriction of visual
field; however this was not indicated or useful for our patient due to her better
functioning OD. Orientation and mobility training can also be recommended for
those with bilaterally reduced peripheral field loss. This training is ideally
implemented prior to symptomatic vision loss to better prepare them for significant
functional vision loss.37-39 For our patient, incorporating scanning techniques to her
left side to compensate for the reduced left field was encouraged.
There are other functional consdierations for patients with RP and macular
degeneration. Driving rehabilitation may assist our patients to drive more
comfortably and safely. Every region has its own regulations regarding driving
requirements and recommendations. For those who no longer meet the
requirements for driving in their jurisdiction, low vision rehabilitation can address
alternate transportation options.40 For school aged children, they may receive
supervision from Teachers of the Visually Impaired (TVI) and be provided with
Individualized Education Programs (IEP).41,42 For those seeking employment, or
currently employed, vocational training or rehabilitative services can be an
option.35,40,41 For the elderly, independent living skills can assist them to better
adapt to their home with the remaining vision.36 With reduced vision, individuals
are more at risk to develop depression, so it is important to provide counseling
services and encourage support from family members.36,43 A visual impairment can
alter quality of life, but it should not prevent anyone from experiencing an
independent fulfilling life.
CONCLUSION
Unilateral RP is a rare presentation of RP. When such a case presents itself, the
clinician must thoroughly evaluate possible mimicries of RP. The literature on URP
is scarce, thus more research is needed to fully understand this condition. It is
important to evaluate the patient’s visual function as a whole, and to consider
education and rehabiliation resources when appropriate to improve visual function.
This case demonstrated that while the complications from her RP OS presented
with peripheral vision issues, when combined with bilateral macular degeneration,
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functional impairment occurred. Early intervention with low vision education was
recommended and will aid the patient if vision continues to change from her
comorbidities.
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